Latest Capital Raising News

New Frontier Minerals has completed a $2.25 million placement to professional investors, issuing over 107 million shares and promising additional attaching options early next year. This capital injection aims to accelerate exploration at its key projects in the Northern Territory and Queensland.

Pathkey.AI Ltd has announced a pro rata non-renounceable rights issue to raise approximately $920,517, alongside a $2.5 million placement, aiming to fund enhancements to its AI platform and strategic expansion.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

Identitii Limited launches a $2.9 million rights issue, underwritten up to $2.3 million by its largest shareholder, to accelerate the commercial rollout of its BNDRY platform.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

HITIQ Limited has successfully raised $925,000 through an oversubscribed placement, issuing shares at a discount and attaching listed options to support its concussion management technology's commercialisation.

L1 Global Long Short Fund Limited has successfully completed its shortfall offer bookbuild, prompting a $62 million institutional placement at $1.63 per share, adding to a total raise of up to $415 million. Trading is set to resume immediately following the announcement.

Global Lithium Resources has released a Definitive Feasibility Study for its Manna Lithium Project, confirming robust financials and a long mine life in Western Australia. The study sets the stage for a Final Investment Decision in 2026 amid improving lithium market conditions.

InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.

FireFly Metals has raised approximately A$139 million to accelerate exploration and development at its Green Bay Copper-Gold Project in Canada, setting the stage for a major resource expansion and a Final Investment Decision in 2026.

Greenvale Energy has raised approximately AUD 856,000 through an oversubscribed Share Purchase Plan, strengthening its uranium exploration efforts in Queensland and the Northern Territory.

BrainChip Holdings has closed its Share Purchase Plan with subscriptions exceeding the $2 million target by nearly $1 million, complementing a recent $35 million placement. The Board’s decision to accept all applications reflects robust shareholder confidence.